Education
About Us
Working with TipRanks
Follow Us
CervoMed (CRVO)
NASDAQ:CRVO
CRVO Stock Chart & Stats
$4.11
-$0.11(-4.76%)
At close: 4:00 PM EST
$4.11
-$0.11(-4.76%)
Day’s Range― - ―
52-Week Range$1.92 - $16.94
Previous CloseN/A
Volume72.82K
Average Volume (3M)112.80K
Market Cap
$37.10M
Enterprise Value$28.59M
Total Cash (Recent Filing)$27.29M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.14
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.84
Shares Outstanding9,252,719
10 Day Avg. Volume143,994
30 Day Avg. Volume112,798
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.48
Price to Sales (P/S)0.00
P/FCF Ratio-1.14
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue88.64
Enterprise Value/Gross Profit88.64
Enterprise Value/Ebitda-1.06
Forecast
1Y Price Target
$22.75Price Target Upside453.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.92
Revenue Forecast (FY)$771.43K
Bulls Say, Bears Say
Bulls Say
Biomarker-driven EnrollmentAnalyst highlights a simple blood biomarker to enrich enrollment for patients most likely to respond, improving the probability of detecting a meaningful clinical benefit in the pivotal study.
Regulatory AlignmentAnalyst notes FDA alignment on a single randomized pivotal trial with agreement on the primary cognitive endpoint and trial design, which clarifies the pathway toward potential approval.
Stable Formulation And ManufacturingStable crystal form and a selected dosing regimen reproduce drug exposures linked to prior clinical and biomarker activity, enabling standardized, scalable manufacturing and potential new patent protection.
Bears Say
Dilution And Financing UncertaintyAnalyst warns the company will need to raise substantial additional capital to complete the pivotal trial, exposing investors to dilution and uncertainty tied to future funding rounds.
Funding Shortfall RiskAnalyst warns available cash appears limited relative to expected cash burn, creating a material risk that additional financing will be required to sustain operations and development programs.
Trial Completion Dependency On FinancingAnalyst cautions the ability to start and complete the pivotal Phase 3 program depends on securing additional funding, which could delay or jeopardize trial timelines if not obtained.
CervoMed News
CRVO FAQ
What was CervoMed’s price range in the past 12 months?
CervoMed lowest stock price was $1.92 and its highest was $16.94 in the past 12 months.
What is CervoMed’s market cap?
CervoMed’s market cap is $37.10M.
When is CervoMed’s upcoming earnings report date?
CervoMed’s upcoming earnings report date is May 19, 2026 which is in 72 days.
How were CervoMed’s earnings last quarter?
CervoMed released its earnings results on Nov 10, 2025. The company reported -$0.84 earnings per share for the quarter, missing the consensus estimate of -$0.657 by -$0.183.
Is CervoMed overvalued?
According to Wall Street analysts CervoMed’s price is currently Undervalued.
Does CervoMed pay dividends?
CervoMed does not currently pay dividends.
What is CervoMed’s EPS estimate?
CervoMed’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CervoMed have?
CervoMed has 9,252,719 shares outstanding.
What happened to CervoMed’s price movement after its last earnings report?
CervoMed reported an EPS of -$0.84 in its last earnings report, missing expectations of -$0.657. Following the earnings report the stock price went down -0.289%.
Which hedge fund is a major shareholder of CervoMed?
Currently, no hedge funds are holding shares in CRVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CervoMed Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.75 (453.53% Upside)
$22.75 (453.53% Upside)
Hedge Fund Trend
Decreased
By 74.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 15.2%
Last 30 Days ▲ 15.2%
News Sentiment
Very Bullish
Bullish news 89%
Bearish news 11%
Bearish news 11%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-49.60%
12-Months-Change
Fundamentals
Return on Equity
-71.42%
Trailing 12-Months
Asset Growth
-28.41%
Trailing 12-Months
Company Description
CervoMed
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
CRVO Stock 12 Month Forecast
Average Price Target
$22.75
▲(453.53% Upside)
Technical Analysis
X4 Pharmaceuticals
―
ABVC BioPharma
―
Jasper Therapeutics
―
Prelude Therapeutics
―
Estrella Immunopharma
―
Ownership Overview
44.08% Insiders
4.04% Mutual Funds
10.02% Other Institutional Investors
38.20% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---